"目錄號: HY-14261
GPCR/G ProteinNeuronal Signaling-
Vilazodone(EMD 68843; SB 659746A)鹽酸鹽是五羥色胺重吸收抑制劑（SSRI）和5-HT1A受體部分激動劑倦春。
5-HT ReceptorSerotonin Transporter
相關(guān)產(chǎn)品
Clozapine N-oxide-Chlorpromazine hydrochloride-Pimavanserin-Fluoxetine hydrochloride-Brexpiprazole-Lorcaserin Hydrochloride-Scopolamine hydrobromide-Paroxetine hydrochloride-Cariprazine hydrochloride-Harmine-Lu AE58054 Hydrochloride-TG6-10-1-Duloxetine hydrochloride-Perphenazine-Sertraline hydrochloride-
生物活性
Description
Vilazodone Hcl (EMD 68843; SB 659746A) is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation for the treatment of major depression.IC50 value:Target: SSRI; 5-HT1AVilazodone represents another option for the treatment of MDD. Vilazodone appears to have a favourable weight-gain profile based on short-term studies. Sexual side-effects were not consistently demonstrated when assessed using clinical rating scales but spontaneously reported AEs related to sexual functioning were observed. Additional controlled data regarding long-term efficacy and effectiveness will help characterise this new agent when used in maintenance treatment.
Clinical Trial
Duke University
Major Depressive Disorder (MDD)
December 2012
Phase 3
University of Texas Southwestern Medical Center-Forest Laboratories
Memory Impairment
December 2012
Phase 2
Forest Laboratories
Major Depressive Disorder
May 2015
Phase 3
The Medical Research Network-Forest Laboratories
Social Anxiety Disorder
October 2012
Forest Laboratories
Major Depressive Disorder
December 2007
Phase 3
Forest Laboratories
Major Depressive Disorder
December 2011
Phase 4
Forest Laboratories
Generalized Anxiety Disorder
April 2013
Phase 3
Thomas Jefferson University-Forest Laboratories
Sexual Dysfunction-Major Depressive Disorder
January 2013
Phase 4
Medical University of South Carolina-National Institute on Drug Abuse (NIDA)
Marijuana Dependence
August 2012
Phase 2
Forest Laboratories
Major Depressive Disorder
April 2012
Phase 4
Forest Laboratories
Major Depressive Disorder
July 2013
Phase 3
New York State Psychiatric Institute-Forest Laboratories
Separation Anxiety Disorder
December 2013
Phase 4
University of Pennsylvania-Forest Laboratories
Hot Flushes
November 2012
University of California, Los Angeles-Forest Laboratories
Major Depressive Disorder
July 2012
Phase 4
Genaissance Pharmaceuticals
Depressive Disorder, Major
February 2006
Phase 3
University of Chicago
Major Depressive Disorder
May 2013
Phase 2
Forest Laboratories
Major Depressive Disorder
March 2008
Phase 3
Massachusetts General Hospital
Major Depressive Disorder-Anxiety-Comorbidity
April 2013
Phase 4
Forest Laboratories
Healthy
March 2014
Phase 1
Forest Laboratories
Generalized Anxiety Disorder
June 2012
Phase 3
Forest Laboratories
Major Depressive Disorder
February 2015
Phase 3
Forest Laboratories
Major Depressive Disorder
December 2011
Phase 4
Pharmacology Research Institute
Major Depressive Disorder
Phase 2
View MoreCollapse
References
